Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
Saved in:
| Title: | Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. |
|---|---|
| Authors: | Pawlyn C; The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.; The Royal Marsden Hospital NHS Foundation Trust, London, UK. charlotte.pawlyn@icr.ac.uk., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit of Leeds, Leeds, UK., Wei LJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Davies F; Perlmutter Cancer Center, NYU Langone, New York, NY, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA, USA., Abdulhaq H; University of California, San Francisco, Fresno Campus, CA, USA., Mateos MV; University Hospital of Salamanca; IBSAL; Institute of Cancer Molecular and Cellular Biology; and CIBERONC, Salamanca, Spain., Laubach J; Dana-Farber Cancer Institute, Boston, MA, USA., Weisel K; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Jackson G; Northern Centre for Cancer Care, Newcastle Upon Tyne Hospitals Trust, Newcastle Upon Tyne, UK., Morgan G; Perlmutter Cancer Center, NYU Langone, New York, NY, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2024 Aug 12; Vol. 14 (1), pp. 134. Date of Electronic Publication: 2024 Aug 12. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39134544 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pawlyn+C%22">Pawlyn C</searchLink>; The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.; The Royal Marsden Hospital NHS Foundation Trust, London, UK. charlotte.pawlyn@icr.ac.uk.<br /><searchLink fieldCode="AU" term="%22Schjesvold+FH%22">Schjesvold FH</searchLink>; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Cairns+DA%22">Cairns DA</searchLink>; Leeds Cancer Research UK Clinical Trials Unit of Leeds, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Wei+LJ%22">Wei LJ</searchLink>; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Davies+F%22">Davies F</searchLink>; Perlmutter Cancer Center, NYU Langone, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Nadeem+O%22">Nadeem O</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Abdulhaq+H%22">Abdulhaq H</searchLink>; University of California, San Francisco, Fresno Campus, CA, USA.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; University Hospital of Salamanca; IBSAL; Institute of Cancer Molecular and Cellular Biology; and CIBERONC, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Laubach+J%22">Laubach J</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Weisel+K%22">Weisel K</searchLink>; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Ludwig+H%22">Ludwig H</searchLink>; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Rajkumar+SV%22">Rajkumar SV</searchLink>; Division of Hematology, Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Sonneveld+P%22">Sonneveld P</searchLink>; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Jackson+G%22">Jackson G</searchLink>; Northern Centre for Cancer Care, Newcastle Upon Tyne Hospitals Trust, Newcastle Upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Morgan+G%22">Morgan G</searchLink>; Perlmutter Cancer Center, NYU Langone, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2024 Aug 12; Vol. 14 (1), pp. 134. <i>Date of Electronic Publication: </i>2024 Aug 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39134544 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41408-024-01109-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 134 Titles: – TitleFull: Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pawlyn C – PersonEntity: Name: NameFull: Schjesvold FH – PersonEntity: Name: NameFull: Cairns DA – PersonEntity: Name: NameFull: Wei LJ – PersonEntity: Name: NameFull: Davies F – PersonEntity: Name: NameFull: Nadeem O – PersonEntity: Name: NameFull: Abdulhaq H – PersonEntity: Name: NameFull: Mateos MV – PersonEntity: Name: NameFull: Laubach J – PersonEntity: Name: NameFull: Weisel K – PersonEntity: Name: NameFull: Ludwig H – PersonEntity: Name: NameFull: Rajkumar SV – PersonEntity: Name: NameFull: Sonneveld P – PersonEntity: Name: NameFull: Jackson G – PersonEntity: Name: NameFull: Morgan G – PersonEntity: Name: NameFull: Richardson PG IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 08 Text: 2024 Aug 12 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2044-5385 Numbering: – Type: volume Value: 14 – Type: issue Value: 1 Titles: – TitleFull: Blood cancer journal Type: main |
| ResultId | 1 |